15/08/2026
🧴 Skin Cancer & Melanoma
From Diagnosis to Treatment
Skin cancer is not a single disease.
When we talk about skin malignancies, we are dealing with different tumors that have different biological behaviors, patterns of spread, prognostic factors, and treatment strategies.
The two major groups encountered in clinical practice are non-melanoma skin cancers, particularly Basal Cell Carcinoma (BCC) and Cutaneous Squamous Cell Carcinoma (cSCC), and melanoma, which arises from melanocytes.
Although they can all develop in the skin, treating them as if they were the same disease would be a major mistake.
Basal Cell Carcinoma — BCC
BCC is usually a slow-growing tumor with a very low tendency for distant metastasis. However, certain tumors can become locally aggressive, particularly when they are located in anatomically difficult areas or have unfavorable features.
The first step is usually a clinical examination followed by biopsy to establish the diagnosis.
For localized disease, surgery is commonly the primary treatment. Depending on the location, size, margins, recurrence, patient factors, and surgical feasibility, radiation therapy may also be considered.
Definitive radiation therapy can be used for selected patients who are not ideal surgical candidates or when surgery would result in unacceptable functional or cosmetic consequences. Postoperative radiation may also be considered when specific high-risk pathological or clinical features are present.
Cutaneous Squamous Cell Carcinoma — cSCC
cSCC behaves differently.
Although many lesions can be cured with local treatment, some tumors have a significantly higher risk of local recurrence, perineural invasion, regional lymph-node involvement, and—in selected cases—distant spread.
Pathology therefore becomes extremely important.
Tumor size, depth, differentiation, perineural invasion, margin status, location, and other pathological features can influence the overall risk assessment and treatment strategy.
Surgery remains an important treatment modality, but radiation therapy can have an important role in selected high-risk cases, particularly when postoperative findings suggest an increased risk of recurrence or when definitive treatment is required.
What about Melanoma?
Melanoma is a completely different story.
It originates from melanocytes and has a much greater potential for lymphatic and hematogenous spread compared with typical BCC.
After biopsy confirms melanoma, management depends heavily on the Breslow thickness, ulceration, mitotic activity, anatomical site, regional nodal status, and presence or absence of distant disease.
For localized melanoma, wide local excision is fundamental. Depending on the characteristics of the primary tumor, evaluation of regional lymph nodes—including sentinel lymph-node assessment—may be considered.
Once regional or metastatic disease is identified, treatment becomes increasingly multidisciplinary.
Modern melanoma management may involve immunotherapy and targeted systemic therapies, particularly in advanced disease. Molecular testing can also influence treatment selection in appropriate patients.
So where does radiation therapy fit?
Radiotherapy is not routinely used for every primary cutaneous melanoma.
Instead, it may have a role in selected situations, such as certain unresectable or recurrent lesions, selected regional disease, palliation of symptomatic metastases, or specific clinical circumstances where local control is important.
This distinction is crucial:
Radiotherapy is not simply another universal treatment for melanoma.
Its role depends on the disease setting and the clinical objective.
The Radiation Oncology Perspective
When radiation therapy is selected for a skin malignancy, treatment planning becomes particularly interesting because the target is often located directly at or very close to the skin surface.
The radiation oncologist must define the clinical target carefully while considering the depth of invasion, surgical bed, potential microscopic extension, and nearby critical structures.
Depending on the situation, treatment may involve superficial or orthovoltage radiation, electrons, or photon-based techniques such as IMRT, with the choice depending on tumor depth, geometry, location, and treatment intent.
For superficial lesions, achieving adequate dose at the skin surface is especially important.
This is where concepts such as bolus, build-up, field margins, and dose fall-off become clinically relevant.
A treatment plan that looks excellent on the screen is not enough.
The dose must cover the area at risk while minimizing unnecessary exposure to structures such as the eyes, lenses, brain, spinal cord, oral cavity, and other nearby organs, depending on tumor location.
Skin cancer demonstrates an important principle in oncology:
The name of the cancer does not determine the treatment by itself.
Histology matters.
Tumor depth matters.
Margins matter.
Perineural invasion matters.
Location matters.
Regional and distant spread matter.
And the patient's overall condition matters.
That is why the same word—"skin cancer"—can lead to completely different treatment pathways.
For one patient, surgery may be sufficient.
For another, postoperative radiation may be considered.
For another, systemic therapy may become the main treatment.
And for selected patients, a combination of modalities may be necessary.
The real goal is not simply to remove or irradiate a visible lesion.
It is to achieve durable tumor control while preserving function, appearance, and quality of life whenever possible.
Different biology.
Different risks.
Different treatment.
One multidisciplinary goal: better patient outcomes.
dranitamalik.com